EUVIMEDObjevte EUVIMED
Open access

Comparing HIV Vaccine Immunogenicity Across Trials With Different Populations and Study Designs

Yutong Jin iD, Alex Luedtke iD, Zoe Moodie iD, Holly Janes, David Benkeser

Statistics in Medicine · 2026-04 · 45 (8-9)

DOI: 10.1002/sim.70495 ↗

At a glance

Journal article in Statistics in Medicine, published online on 2026-04-01. Written by Yutong Jin and 4 co-authors. Institution: Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, USA. Major MEDLINE topics: AIDS Vaccines, HIV Infections, Immunogenicity, Vaccine, Randomized Controlled Trials as Topic. 24 references. The full text is freely available in PubMed Central. Funded by: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Safe and effective preventive vaccines have the potential to help stem the HIV epidemic. The efficacy of such vaccines is typically measured in randomized, double‐blind phase IIb/III trials and described as a reduction in newly acquired HIV infections. However, such trials are often expensive, time‐consuming, and/or logistically challenging. These challenges lead to a great interest in immune responses induced by vaccination, and in identifying which immune responses predict vaccine efficacy. These responses are termed vaccine correlates of protection . Studies of vaccine‐induced immunogenicity vary in size and design, ranging from small, early‐phase trials to case‐control studies nested in a broader late‐phase randomized trial. Moreover, trials can be conducted in geographically diverse study populations across the world. Such diversity presents a challenge for objectively comparing vaccine‐induced immunogenicity. To address these practical challenges, we propose a framework that is capable of identifying appropriate causal estimands and estimators, which can be used to provide standardized comparisons of vaccine‐induced immunogenicity across trials. We evaluate the performance of the proposed estimands via extensive simulation studies. Our estimators are well‐behaved and enjoy robustness properties. The proposed technique is applied to compare vaccine immunogenicity using data from three recent HIV vaccine trials.

Subjects

MeSH terms (MEDLINE)

AIDS VaccinesHIV InfectionsImmunogenicity, VaccineRandomized Controlled Trials as TopicHumansVaccine EfficacyResearch DesignComputer SimulationDouble-Blind Method

Author keywords

HIV/AIDScausal inferenceinfectious diseaserandomized clinical trialsvaccine immunogenicity

Substances

AIDS Vaccines

Authors and institutions

  • Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, USA.
  • Department of Statistics, University of Washington, Seattle, Washington, USA.
  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

ORCID profiles: Yutong Jin, Alex Luedtke, Zoe Moodie

Funding

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Cite

APA

Jin, Y., Luedtke, A., Moodie, Z., Janes, H., & Benkeser, D. (2026). Comparing HIV Vaccine Immunogenicity Across Trials With Different Populations and Study Designs. Statistics in Medicine, 45(8-9). https://doi.org/10.1002/sim.70495

Vancouver

Jin Y, Luedtke A, Moodie Z, Janes H, Benkeser D. Comparing HIV Vaccine Immunogenicity Across Trials With Different Populations and Study Designs. Statistics in Medicine. 2026;45(8-9). doi:10.1002/sim.70495

BibTeX
@article{Jin2026,
  author = {Jin, Yutong and Luedtke, Alex and Moodie, Zoe and Janes, Holly and Benkeser, David},
  title = {Comparing HIV Vaccine Immunogenicity Across Trials With Different Populations and Study Designs},
  journal = {Statistics in Medicine},
  year = {2026},
  volume = {45},
  number = {8-9},
  doi = {10.1002/sim.70495}
}
Start for free →